Although a few studies have investigated the role of glycosylation in Tregs and Foxp3 regulation, the potential of O-GlcNAcylation targeted therapy in modulating the function of Tregs should be investigated to achieve anti-tumor and anti-autoimmune immunity (Figure 2E). This evidence concerns the gene FOXP3 and neoplasm.